SCHEMBL4066314

SCHEMBL4066314

CCCCCCCCCCCCN(C)CCC(=O)O.[NaH]

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 9/20 0.70
KDM5A P29375 7/20 0.70
PHF8 Q9UPP1 2/20 0.70
KDM5C P41229 1/20 0.67
KDM5B Q9UGL1 1/20 0.67
KDM4A O75164 2/20 0.65
GPR84 Q9NQS5 7/20 0.56
PPARG P37231 6/20 0.56
PPARD Q03181 6/20 0.56
PPARA Q07869 6/20 0.56
HDAC11 Q96DB2 5/20 0.56
TSHR P16473 4/20 0.56
ALDH1A1 P00352 2/20 0.56
TLR2 O60603 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
FABP4 P15090 2/20 0.56
PTPN1 P18031 2/20 0.56
SLC22A6 Q4U2R8 1/20 0.56
SLC22A8 Q8TCC7 1/20 0.56
MEN1 O00255 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22534546 1.00 KDM4C (0.70) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL29380393 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL11587594 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL27622230 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL5984578 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL28434194 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL8341418 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL8626544 0.98 KDM4C (0.69) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL8359768 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B
SCHEMBL16492835 0.98 KDM4C (0.72) KDM4CKDM5APHF8KDM5CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009088119-A1 COMPOSITION FOR PREVENTING OR TREATING DRY EYE SYNDROME COMPRISING POLY-GAMMA-GLUTAMIC ACID BIOLEADERS CORPORATION (KR) 2009-07-16 WO disclosed
US-20040091438-A1 Polyorganosiloxane emulsions,process for producing the same and material for cosmetic preparation DOW CORNING TORAY SILICONE CO. LTD. (JP) 2004-05-13 US disclosed
EP-1394215-A1 POLYORGANOSILOXANE EMULSION, PROCESS FOR PRODUCING THE SAME, AND MATERIAL FOR COSMETIC PREPARATION Dow Corning Toray Silicone Co., Ltd. (JP) 2004-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040091438-A1 Polyorganosiloxane emulsions,process for producing the same and material for cosmetic preparation CUTA, UNG, PCNA KDM4C 2628/4885KDM5A 813/4885PHF8 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.